Sudeep Pharma Ltd appointed Mr. Milin Mehta as an Additional Director in the category of Non-Executive Non-Independent Director effective June 26, 2026. The appointment is subject to the approval of the shareholders of the company. The Board of Directors approved the appointment during its meeting held on June 26, 2026. The director is liable to retire by rotation.

The company confirmed that Mr. Milin Mehta has not been debarred from holding the office of Director by virtue of any SEBI Order or any other Authority. This confirmation was provided in compliance with a SEBI Letter dated June 14, 2018 and a BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018.

Mr. Mehta is the Managing Partner at K C Mehta & Co LLP and has been associated with the firm for over three decades. He is a Chartered Accountant and Law Graduate. He secured a rank in the CA exams and received a Gold Medal in M.Com. from The Maharaja Sayajirao University of Baroda.

Under his leadership, the firm expanded its geographic reach and service capabilities. He established the firm’s International Tax and Transfer Pricing practice and currently leads the Transaction Advisory Services vertical. He continues to guide the Tax and Regulatory practice.

Mr. Mehta has represented clients in complex tax litigation and has contributed to national policy initiatives, including the formulation of the Income Computation and Disclosure Standards (ICDS). He has served as Vice Chairman and Treasurer of the Western India Regional Council of ICAI. He is not related to any Director(s) of the Company as defined under the provisions of Section 2(77) of Companies Act, 2013.

Director Details

Sudeep Pharma reported a 27.9% year-on-year increase in revenue from operations to ₹642.3 crore for the fiscal year 2026, compared to ₹501.9 crore in FY25. Profit after tax (PAT) for the year stood at ₹174.3 crore, up from ₹138.7 crore in the previous year, while EBITDA grew by 16.8% to ₹221.9 crore. The company disclosed these figures in its earnings call transcript submitted to the exchanges under Regulation 30 of the SEBI Listing Regulations, 2015.

For the fourth quarter of FY26, revenue from operations grew by 15.7% to ₹182.3 crore, with PAT for the quarter rising to ₹48.5 crore. EBITDA for Q4 FY26 stood at ₹62.6 crores, with a margin of 34.3%. The financial performance was achieved despite a volatile operating environment characterized by geopolitical uncertainties and inflation in raw material prices.

Financial Highlights

Operational and Strategic Updates

The company’s specialty ingredients vertical reported revenue growth of 62% to ₹280 crore, increasing its contribution to total revenue from 34% in FY25 to 44% in FY26. The pharma food and nutrition vertical grew by 10% during the year, contributing 56% to total revenue. Export business accounted for 60% of the total revenue mix.

Sudeep Pharma provided an update on its battery materials project at Dahej, Gujarat, confirming that Phase 1 capacity of 25,000 metric tons per year is on track for commissioning by April 2027. The company has engaged with 42 customers globally and has started receiving initial commercial purchase orders, including approximately 700 metric tons recently. The new greenfield manufacturing facility has completed internal production validation, and the customer approval process is underway.

Balance Sheet and Outlook

Working capital days increased to 213 days from 184 days, primarily due to a strategic increase in inventory to mitigate procurement risks and support customer commitments. The company’s net debt stood at ₹33.6 crore as of March 31, 2026, with a net debt-to-equity ratio of 0.04x. Management indicated a focus on normalizing the working capital cycle to 150–160 days within the current financial year.